Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SENP2 | Q9HC62 | 2/20 | 0.66 |
| ▸ | SENP1 | Q9P0U3 | 2/20 | 0.66 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.66 |
| ▸ | SUMO1 | P63165 | 1/20 | 0.66 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.66 |
| ▸ | SENP3 | Q9H4L4 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14988194 | 1.00 | SENP2 (0.66) | SENP2SENP1SUMO2SUMO1SENP7 | |
| SCHEMBL29697216 | 0.99 | SENP2 (0.67) | SENP2SENP1SUMO2SUMO1SENP7 | |
| SCHEMBL18044286 | 0.99 | SENP2 (0.67) | SENP2SENP1SUMO2SUMO1SENP7 | |
| SCHEMBL905113 | 0.99 | SENP2 (0.67) | SENP2SENP1SUMO2SUMO1SENP7 | |
| SCHEMBL14988766 | 0.93 | SENP2 (0.60) | SENP2SENP1SUMO2SUMO1SENP7 | |
| SCHEMBL14988763 | 0.93 | SENP2 (0.60) | SENP2SENP1SUMO2SUMO1SENP7 | |
| SCHEMBL15120197 | 0.92 | SENP2 (0.61) | SENP2SENP1SUMO2SUMO1SENP7 | |
| SCHEMBL29697067 | 0.92 | SENP2 (0.61) | SENP2SENP1SUMO2SUMO1SENP7 | |
| SCHEMBL18044239 | 0.92 | SENP2 (0.61) | SENP2SENP1SUMO2SUMO1SENP7 | |
| SCHEMBL17319311 | 0.90 | SENP2 (0.69) | SENP2SENP1SUMO2SUMO1SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206129-B2 | Agent for treatment of eye diseases | DAITO CHEMIX CORPORATION (JP) | 2015-12-08 | — | — | US | claimed |
| US-20240216397-A1 | COMPOSITION FOR AMELIORATING SKIN TISSUE ABNORMALITY | KYOTO UNIVERSITY (JP) | 2024-07-04 | — | — | US | disclosed |
| US-12011438-B2 | Composition for protecting cardiomyocyte | KYOTO UNIVERSITY (JP) | 2024-06-18 | — | — | US | disclosed |
| EP-4331589-A1 | COMPOSITION FOR AMELIORATING ABNORMALITY OF SKIN TISSUE | Kyoto University (JP) | 2024-03-06 | — | — | EP | disclosed |
| US-20220401461-A1 | Pharmaceutical Composition for Protecting Cartilage | KYOTO UNIVERSITY (JP) | 2022-12-22 | — | — | US | disclosed |
| EP-3733177-B1 | COMPOSITION FOR PROTECTING CORNEA | UNIV KYOTO (JP) | 2022-07-06 | — | — | EP | disclosed |
| EP-3848029-A1 | MEDICINE COMPOSITION FOR TREATING CEREBRAL INFARCTION | Kyoto University (JP) | 2021-07-14 | — | — | EP | disclosed |
| US-20210145808-A1 | Composition for Protecting Cardiomyocyte | KYOTO UNIVERSITY (JP) | 2021-05-20 | — | — | US | disclosed |
| US-20210137950-A1 | Pharmaceutical Composition for Treating Cerebral Infarction | KYOTO UNIVERSITY (JP) | 2021-05-13 | — | — | US | disclosed |
| US-20210059995-A1 | Composition for Protecting Cornea | KYOTO UNIVERSITY (JP) | 2021-03-04 | — | — | US | disclosed |
| EP-2599771-B1 | NAPHTHALENE DERIVATIVE | DAITO CHEMIX CORP (JP) | 2016-09-14 | — | — | EP | disclosed |
| EP-3042658-A1 | MEDICINAL COMPOSITION IMPROVING LEPTIN RESISTANCE | Kyoto University (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160000810-A1 | Method For Treating Eye Diseases | KYOTO UNIVERSITY (JP) | 2016-01-07 | — | — | US | disclosed |
| EP-2959903-A1 | MEDICINE FOR TREATING EYE DISEASE | Kyoto University (JP) | 2015-12-30 | — | — | EP | disclosed |
| US-9206129-B2 | Agent for treatment of eye diseases | DAITO CHEMIX CORPORATION (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-2623494-B1 | AGENT FOR TREATMENT OF EYE DISEASES | DAITO CHEMIX CORP (JP) | 2015-09-02 | — | — | EP | disclosed |
| US-20140148416-A1 | Agent for Treatment of Eye Diseases | KYOTO UNIVERSITY (JP) | 2014-05-29 | — | — | US | disclosed |
| EP-2623494-A1 | AGENT FOR TREATMENT OF EYE DISEASES | Daito Chemix Corporation (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130184241-A1 | Naphthalene Derivative | KYOTO UNIVERSITY (JP) | 2013-07-18 | — | — | US | disclosed |
| EP-2599771-A1 | NAPHTHALENE DERIVATIVE | Daito Chemix Corporation (JP) | 2013-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000810-A1 | Method For Treating Eye Diseases | CFB, AGER, CFH | SENP2 3567/4885SENP1 3495/4885SUMO2 3428/4885 |
| US-12011438-B2 | Composition for protecting cardiomyocyte | TNNI3, TNNT2, TNNC1 | SENP2 2730/4885SENP1 1865/4885SUMO2 2295/4885 |
| US-20140148416-A1 | Agent for Treatment of Eye Diseases | PDE6A, ALDH1A2, PDE6D | SENP2 3080/4885SENP1 3643/4885SUMO2 3028/4885 |
| US-20130184241-A1 | Naphthalene Derivative | VCP, NOC2L, VAT1 | SENP2 754/4885SENP1 615/4885SUMO2 1084/4885 |
| US-20210145808-A1 | Composition for Protecting Cardiomyocyte | TNNI3, TNNT2, TNNC1 | SENP2 2730/4885SENP1 1865/4885SUMO2 2295/4885 |
| US-20220401461-A1 | Pharmaceutical Composition for Protecting Cartilage | COL2A1, MATR3, COL1A1 | SENP2 2405/4885SENP1 1400/4885SUMO2 2757/4885 |
| US-20210059995-A1 | Composition for Protecting Cornea | VCL, VASP, VCP | SENP2 1122/4885SENP1 555/4885SUMO2 1484/4885 |
| US-20240216397-A1 | COMPOSITION FOR AMELIORATING SKIN TISSUE ABNORMALITY | CUTA, FABP4, MMP13 | SENP2 3876/4885SENP1 3680/4885SUMO2 3580/4885 |
| US-20210137950-A1 | Pharmaceutical Composition for Treating Cerebral Infarction | APOB, PLAT, PLA2G7 | SENP2 2762/4885SENP1 3636/4885SUMO2 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.